[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
…, N Harbeck, CS Huang, J Huober, A Ilbawi, Z Jiang… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
…, DF Hayes, CA Hudis, JN Ingle, J Jassem, Z Jiang… - Annals of oncology, 2013 - Elsevier
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed
and endorsed substantial new evidence on aspects of the local and regional therapies for …
and endorsed substantial new evidence on aspects of the local and regional therapies for …
[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …
…, J Huober, CA Hudis, JN Ingle, J Jassem, Z Jiang… - Annals of oncology, 2015 - Elsevier
The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …
new evidence on locoregional and systemic therapies for early breast cancer. Further …
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
HJ Burstein, Y Sun, LY Dirix, Z Jiang, R Paridaens… - J Clin Oncol, 2010 - ejcancer.com
Purpose Neratinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor. The
efficacy and safety of neratinib were evaluated in two cohorts of patients with advanced ErbB2-…
efficacy and safety of neratinib were evaluated in two cohorts of patients with advanced ErbB2-…
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a …
…, H Iwata, J Cortés, M De Laurentiis, Z Jiang… - The Lancet …, 2017 - thelancet.com
Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine
therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed …
therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed …
[HTML][HTML] Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer
…, Y Yuan, Y Liu, Y Cong, B Ding, Z Jiang… - Nature …, 2021 - nature.com
Molecular profiling of circulating extracellular vesicles (EVs) provides a promising noninvasive
means to diagnose, monitor, and predict the course of metastatic breast cancer (MBC). …
means to diagnose, monitor, and predict the course of metastatic breast cancer (MBC). …
Pyrotinib or lapatinib combined with capecitabine in HER2–positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: A randomized …
F Ma, Q Ouyang, W Li, Z Jiang, Z Tong, Y Liu… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity
and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of …
and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of …
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer
X Hu, J Zhang, B Xu, Z Jiang, J Ragaz… - … journal of cancer, 2014 - Wiley Online Library
Apatinib is an oral, highly potent tyrosine‐kinase inhibitor targeting VEGFR2. Phase I study
showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase …
showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase …
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3 …
Background mTOR inhibition reverses trastuzumab resistance via the hyperactivated PIK/AKT/mTOR
pathway due to PTEN loss, by sensitising PTEN-deficient tumours to trastuzumab. …
pathway due to PTEN loss, by sensitising PTEN-deficient tumours to trastuzumab. …
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo …
Z Jiang, W Li, X Hu, Q Zhang, T Sun, S Cui… - The Lancet …, 2019 - thelancet.com
Background Tucidinostat (formerly known as chidamide) is an oral subtype-selective
histone deacetylase inhibitor. In an exploratory study, the combination of tucidinostat with …
histone deacetylase inhibitor. In an exploratory study, the combination of tucidinostat with …